Monitor next 10-Q for disclosure of stock-based compensation expense related to these awards. The vesting commencement in July 2026 may attract minor attention but is not a catalyst for significant stock movement.
Price Chart
Executive Summary
John M. Gay, Chief Financial Officer of Pelthos Therapeutics Inc., filed a Form 3 disclosing initial beneficial ownership of equity awards granted in 2025, including 30,518 restricted stock units (RSUs) and stock options to purchase 93,000 shares at $13.50 per share. The filing is routine and reflects standard compensation arrangements.
Key Facts
- John M. Gay, CFO, filed Form 3 for initial beneficial ownership as of April 10, 2026, reporting equity awards granted on July 2, 2025.
- The filing includes 30,518 RSUs that vest one-third on July 2, 2026, and ratably quarterly over the following two years.
- Also included are stock options to purchase 93,000 shares at $13.50 per share, with identical vesting terms.
- No shares were acquired or sold in this filing; it is a required initial ownership disclosure under Section 16.
Financial Impact
No immediate financial impact. Awards were granted in 2025 and this is a delayed reporting requirement. Total potential dilution from unvested RSUs and options is 123,518 shares, or approximately 0.16% of a $77M market cap at current price.
Risk Factors
- Potential for increased share dilution if all options and RSUs vest and settle.
- Perception of delayed filing could raise governance concerns if not explained.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001919246-26-000063 |
| Document: 0001919246-26-000063-index.html | 0001919246-26-000063 |
| Document: 0001919246-26-000063.txt | 0001919246-26-000063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers